- Home
- EVCM vs ZYME Comparison
EVCM vs ZYME Comparison
Compare EVCM & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVCM | ZYME |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | EVCM | ZYME |
|---|---|---|
| Price | $11.63 | $26.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $10.67 | ★ $38.90 |
| AVG Volume (30 Days) | 90.3K | ★ 517.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.45 | 33.33 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $588,907,000.00 | $105,965,000.00 |
| Revenue This Year | $7.39 | $183.10 |
| Revenue Next Year | $5.84 | N/A |
| P/E Ratio | $121.70 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $7.66 | $10.89 |
| 52 Week High | $14.41 | $29.75 |
Technical Indicators
Market Signals| Indicator | EVCM | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 49.47 |
| Support Level | $10.70 | $22.28 |
| Resistance Level | $12.09 | $27.35 |
| Average True Range (ATR) | 0.57 | 1.03 |
| MACD | -0.04 | -0.23 |
| Stochastic Oscillator | 32.86 | 11.52 |
Price Performance
Historical ComparisonAbout EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. The Company served more than 745,000 customers across three core verticals: EverPro for Home Services; EverHealth for Health Services; and EverWell for Wellness Services. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.